Today, FDA’s Oncologic Drugs Advisory Committee voted unanimously (12/12) in favor of the use of MRD as an endpoint to support accelerated approval of new therapies for patients with multiple myeloma. This is fantastic news for the hematology community, with the potential to bring life-saving therapies to patients sooner. https://lnkd.in/gkTUhEEq
Adaptive Biotechnologies Corp.
生物技术
Seattle，WA 30,007 位关注者
Every immune system has a story to tell; the key is knowing how to listen.
关于我们
Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems. Adaptive’s proprietary immune profiling platform reveals and translates insights from our adaptive immune systems with unprecedented scale and precision. Working with drug developers, clinicians and academic researchers, we are applying these insights to develop products that will transform the way diseases -- such as cancer, autoimmune conditions, and infectious diseases -- are diagnosed and treated. For more information, please visit adaptivebiotech.com.
- 网站
-
https://www.adaptivebiotech.com
Adaptive Biotechnologies Corp.的外部链接
- 所属行业
- 生物技术
- 规模
- 501-1,000 人
- 总部
- Seattle，WA
- 类型
- 上市公司
- 创立
- 2009
- 领域
- Biotechnology、Research、Diagnostic和Therapeutics
地点
Adaptive Biotechnologies Corp.员工
-
Erica Hesse
-
John Alsobrook II, PhD, DABCC, FAACC
-
Theresa Nicoletto, MBA
Rare Disease Sales and Management | Patient Advocacy | Business Development | Product Launch Experiences | Sales Training | Managed Care |…
-
Mary Pat Lancelotta
Biotech and Life Sciences Commercial Executive | Board Member
动态
-
This World Cancer Day, hear from Jim, a patient with DLBCL and an avid cyclist, about how MRD testing results empowered him to live a normal life. #WorldCancerDay #Oncology #MRDTesting #UnitedbyUnique https://bit.ly/4gsqMvf
Jim - DLBCL Patient
https://wistia.com
-
During the month of February, Adaptive will celebrate and honor #BlackHistoryMonth. Through educational programming and events hosted by our?Black Adapter Network (BAN), we are building safe spaces to openly discuss Black history, culture, and its continued influence on today’s climate to bridge gaps on sensitive issues. #BeAdaptive
-
-
The 2024 ASH annual meeting included almost 300 abstracts that included MRD testing results. Hear from leading experts, including Rahul Banerjee, Aaron Logan, and Timothy Fenske about their key takeaways and implications. Register: https://bit.ly/40worun
-
-
Adaptive is proud to be recognized by the Human Rights Campaign Foundation’s 2025 Corporate Equality Index with a score of 80 out of 100. This milestone reflects our ongoing commitment to fostering an inclusive workplace for our LGBTQ+ team members. We’re excited to continue building a culture where everyone can thrive. Learn more: https://bit.ly/4271Jdr
-
CEO Chad Robins will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14 at 5:15 p.m. PT. Access to the live and archived webcast of the presentation will be available on the “Investors” section of the Adaptive website. https://lnkd.in/gPiDZM2v
-
-
Strong new evidence at #ASH24 demonstrate that acting on a clonoSEQ MRD result can benefit patients across a variety of disease states and treatment settings. Read the press release: https://lnkd.in/g6syAgDa clonoSEQ is FDA-cleared to assess MRD in MM, CLL and ALL; CLIA-validated as an LDT. For sample types & test limitations: https://rb.gy/8tju9y
-